Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18204
Country/Region: Kenya
Year: 2018
Main Partner: University of Nairobi
Main Partner Program: NA
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $3,792,880 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $241,916
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $517,298
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $455,456
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $2,413,414
Treatment: Pediatric Treatment (PDTX) $164,796
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_SELF 2019 1,166
HTS_SELF 15-19, Female, Directly-Assisted 2019 62
HTS_SELF 15-19, Female, Unassisted 2019 62
HTS_SELF 15-19, Male, Directly-Assisted 2019 21
HTS_SELF 15-19, Male, Unassisted 2019 21
HTS_SELF 20-24, Female, Directly-Assisted 2019 62
HTS_SELF 20-24, Female, Unassisted 2019 62
HTS_SELF 20-24, Male, Directly-Assisted 2019 21
HTS_SELF 20-24, Male, Unassisted 2019 21
HTS_SELF 25-29, Female, Directly-Assisted 2019 62
HTS_SELF 25-29, Female, Unassisted 2019 62
HTS_SELF 25-29, Male, Directly-Assisted 2019 21
HTS_SELF 25-29, Male, Unassisted 2019 21
HTS_SELF 30-34, Female, Directly-Assisted 2019 62
HTS_SELF 30-34, Female, Unassisted 2019 62
HTS_SELF 30-34, Male, Directly-Assisted 2019 21
HTS_SELF 30-34, Male, Unassisted 2019 21
HTS_SELF 35-39, Female, Directly-Assisted 2019 62
HTS_SELF 35-39, Female, Unassisted 2019 62
HTS_SELF 35-39, Male, Directly-Assisted 2019 21
HTS_SELF 35-39, Male, Unassisted 2019 21
HTS_SELF 40-49, Female, Directly-Assisted 2019 62
HTS_SELF 40-49, Female, Unassisted 2019 62
HTS_SELF 40-49, Male, Directly-Assisted 2019 21
HTS_SELF 40-49, Male, Unassisted 2019 21
HTS_SELF 50+, Female, Directly-Assisted 2019 62
HTS_SELF 50+, Female, Unassisted 2019 62
HTS_SELF 50+, Male, Directly-Assisted 2019 21
HTS_SELF 50+, Male, Unassisted 2019 21
HTS_SELF Directly-Assisted 2019 583
HTS_SELF FSW, Directly-Assisted 2019 783
HTS_SELF MSM, Directly-Assisted 2019 175
HTS_SELF PWID, Directly-Assisted 2019 70
HTS_SELF Unassisted 2019 583
HTS_SELF Unassisted - Other 2019 59
HTS_SELF Unassisted - Self 2019 292
HTS_SELF Unassisted - Sex Partner 2019 234
HTS_TST 15-19, Female, Negative 2019 380
HTS_TST 15-19, Male, Negative 2019 44
HTS_TST 20-24, Female, Negative 2019 1,310
HTS_TST 20-24, Male, Negative 2019 140
HTS_TST 25-29, Female, Negative 2019 2,126
HTS_TST 25-29, Female, Negative 2019 148
HTS_TST 25-29, Female, Negative 2019 20,134
HTS_TST 25-29, Female, Negative 2019 5,497
HTS_TST 25-29, Female, Negative 2019 740
HTS_TST 25-29, Female, Negative 2019 118
HTS_TST 25-29, Female, Negative 2019 4,396
HTS_TST 25-29, Female, Negative 2019 1,420
HTS_TST 25-29, Male, Negative 2019 170
HTS_TST 25-29, Male, Negative 2019 10
HTS_TST 25-29, Male, Negative 2019 8,169
HTS_TST 25-29, Male, Negative 2019 56
HTS_TST 25-29, Male, Negative 2019 156
HTS_TST 25-29, Male, Negative 2019 401
HTS_TST 25-29, Male, Negative 2019 107
HTS_TST 30-34, Female, Negative 2019 2,430
HTS_TST 30-34, Female, Negative 2019 169
HTS_TST 30-34, Female, Negative 2019 22,353
HTS_TST 30-34, Female, Negative 2019 5,497
HTS_TST 30-34, Female, Negative 2019 847
HTS_TST 30-34, Female, Negative 2019 107
HTS_TST 30-34, Female, Negative 2019 5,024
HTS_TST 30-34, Female, Negative 2019 1,622
HTS_TST 30-34, Male, Negative 2019 127
HTS_TST 30-34, Male, Negative 2019 204
HTS_TST 30-34, Male, Negative 2019 12
HTS_TST 30-34, Male, Negative 2019 10,109
HTS_TST 30-34, Male, Negative 2019 67
HTS_TST 30-34, Male, Negative 2019 167
HTS_TST 30-34, Male, Negative 2019 481
HTS_TST 35-39, Female, Negative 2019 405
HTS_TST 35-39, Female, Negative 2019 607
HTS_TST 35-39, Female, Negative 2019 42
HTS_TST 35-39, Female, Negative 2019 7,507
HTS_TST 35-39, Female, Negative 2019 5,497
HTS_TST 35-39, Female, Negative 2019 211
HTS_TST 35-39, Female, Negative 2019 132
HTS_TST 35-39, Female, Negative 2019 1,256
HTS_TST 35-39, Male, Negative 2019 127
HTS_TST 35-39, Male, Negative 2019 204
HTS_TST 35-39, Male, Negative 2019 12
HTS_TST 35-39, Male, Negative 2019 2,432
HTS_TST 35-39, Male, Negative 2019 67
HTS_TST 35-39, Male, Negative 2019 234
HTS_TST 35-39, Male, Negative 2019 481
HTS_TST 40-49, Female, Negative 2019 405
HTS_TST 40-49, Female, Negative 2019 607
HTS_TST 40-49, Female, Negative 2019 42
HTS_TST 40-49, Female, Negative 2019 7,507
HTS_TST 40-49, Female, Negative 2019 5,497
HTS_TST 40-49, Female, Negative 2019 211
HTS_TST 40-49, Female, Negative 2019 106
HTS_TST 40-49, Female, Negative 2019 1,256
HTS_TST 40-49, Male, Negative 2019 42
HTS_TST 40-49, Male, Negative 2019 68
HTS_TST 40-49, Male, Negative 2019 4
HTS_TST 40-49, Male, Negative 2019 811
HTS_TST 40-49, Male, Negative 2019 22
HTS_TST 40-49, Male, Negative 2019 215
HTS_TST 40-49, Male, Negative 2019 161
HTS_TST 50+, Female, Negative 2019 106
HTS_TST 50+, Male, Negative 2019 12
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 264,592
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Female, Negative 2019 66
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Male, Negative 2019 3
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Female, Negative 2019 228
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Male, Negative 2019 11
HTS_TST Service Delivery Point (Community) Index Mod: 50+, Female, Negative 2019 21
HTS_TST Service Delivery Point (Community) Index Mod: 50+, Male, Negative 2019 2
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2019 11
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 3,112
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 12,476
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2019 33
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 257
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 604
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 232
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 174
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 724
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 81
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 2,493
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 2,413
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 203
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 22
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2019 19
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 41
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 17
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 12
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 1,211
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 191
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 4,172
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 612
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 304
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 34
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 1,390
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 400
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 429
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 9,460
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 6,474
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 48,453
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 5,976
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 3,754
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 405
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 239
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 68
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 83
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 76
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 124
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 151
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 124
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 151
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 99
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 175
HTS_TST Service Delivery Point (Facility) VCT: <1, Negative 2019 8
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2019 94
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 20
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 31
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 3,067
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 705
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 10,565
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 2,256
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 628
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 80
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 331
HTS_TST_POS 15-19, Female, Positive 2019 2
HTS_TST_POS 20-24, Female, Positive 2019 8
HTS_TST_POS 25-29, Female, Positive 2019 58
HTS_TST_POS 25-29, Female, Positive 2019 16
HTS_TST_POS 25-29, Female, Positive 2019 571
HTS_TST_POS 25-29, Female, Positive 2019 122
HTS_TST_POS 25-29, Female, Positive 2019 4
HTS_TST_POS 25-29, Female, Positive 2019 20
HTS_TST_POS 25-29, Female, Positive 2019 164
HTS_TST_POS 25-29, Female, Positive 2019 247
HTS_TST_POS 25-29, Male, Positive 2019 4
HTS_TST_POS 25-29, Male, Positive 2019 1
HTS_TST_POS 25-29, Male, Positive 2019 219
HTS_TST_POS 25-29, Male, Positive 2019 26
HTS_TST_POS 25-29, Male, Positive 2019 14
HTS_TST_POS 25-29, Male, Positive 2019 18
HTS_TST_POS 30-34, Female, Positive 2019 66
HTS_TST_POS 30-34, Female, Positive 2019 19
HTS_TST_POS 30-34, Female, Positive 2019 636
HTS_TST_POS 30-34, Female, Positive 2019 122
HTS_TST_POS 30-34, Female, Positive 2019 5
HTS_TST_POS 30-34, Female, Positive 2019 17
HTS_TST_POS 30-34, Female, Positive 2019 187
HTS_TST_POS 30-34, Female, Positive 2019 281
HTS_TST_POS 30-34, Male, Positive 2019 21
HTS_TST_POS 30-34, Male, Positive 2019 6
HTS_TST_POS 30-34, Male, Positive 2019 1
HTS_TST_POS 30-34, Male, Positive 2019 271
HTS_TST_POS 30-34, Male, Positive 2019 28
HTS_TST_POS 30-34, Male, Positive 2019 17
HTS_TST_POS 35-39, Female, Positive 2019 71
HTS_TST_POS 35-39, Female, Positive 2019 17
HTS_TST_POS 35-39, Female, Positive 2019 5
HTS_TST_POS 35-39, Female, Positive 2019 211
HTS_TST_POS 35-39, Female, Positive 2019 102
HTS_TST_POS 35-39, Female, Positive 2019 1
HTS_TST_POS 35-39, Female, Positive 2019 22
HTS_TST_POS 35-39, Female, Positive 2019 47
HTS_TST_POS 35-39, Male, Positive 2019 21
HTS_TST_POS 35-39, Male, Positive 2019 6
HTS_TST_POS 35-39, Male, Positive 2019 1
HTS_TST_POS 35-39, Male, Positive 2019 65
HTS_TST_POS 35-39, Male, Positive 2019 38
HTS_TST_POS 35-39, Male, Positive 2019 17
HTS_TST_POS 40-49, Female, Positive 2019 71
HTS_TST_POS 40-49, Female, Positive 2019 17
HTS_TST_POS 40-49, Female, Positive 2019 5
HTS_TST_POS 40-49, Female, Positive 2019 211
HTS_TST_POS 40-49, Female, Positive 2019 62
HTS_TST_POS 40-49, Female, Positive 2019 1
HTS_TST_POS 40-49, Female, Positive 2019 17
HTS_TST_POS 40-49, Female, Positive 2019 47
HTS_TST_POS 40-49, Male, Positive 2019 7
HTS_TST_POS 40-49, Male, Positive 2019 2
HTS_TST_POS 40-49, Male, Positive 2019 21
HTS_TST_POS 40-49, Male, Positive 2019 36
HTS_TST_POS 40-49, Male, Positive 2019 6
HTS_TST_POS 50+, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Community) Index Mod: 15-19, Female, Positive 2019 7
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Female, Positive 2019 25
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Community) Index Mod: 50+, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 41
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 134
HTS_TST_POS Service Delivery Point (Facility) Index: <1, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 124
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 411
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 54
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 35
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 29
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 100
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 16
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 244
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 161
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 1,267
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 121
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 105
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 14
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 21
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 25
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 21
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 25
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 16
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 29
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 99
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 18
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 340
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 57
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 24
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 3
PMTCT_ART Already on ART at beginning of current pregnancy 2019 782
PMTCT_ART New on ART 2019 553
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 1,335
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 40,776
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 124
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 124
PMTCT_EID Sum of Infant Age disaggregates 2019 124
PMTCT_STAT 25-29, Female 2019 6,000
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 166
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 5,828
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 80
PMTCT_STAT 30-34, Female 2019 6,000
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 166
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 5,828
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 80
PMTCT_STAT 35-39, Female 2019 6,000
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 166
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 5,828
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 80
PMTCT_STAT 40-49, Female 2019 6,000
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 166
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 5,828
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 80
PMTCT_STAT By Age (Numerator): 10-14 2019 12
PMTCT_STAT By Age (Numerator): 15-19 2019 3,282
PMTCT_STAT By Age (Numerator): 20-24 2019 13,475
PMTCT_STAT By Age (Numerator): 50+ 2019 36
PMTCT_STAT By Number of known positives: 15-19 2019 15
PMTCT_STAT By Number of known positives: 20-24 2019 140
PMTCT_STAT By Number of new negative: 10-14 2019 12
PMTCT_STAT By Number of new negative: 15-19 2019 3,265
PMTCT_STAT By Number of new negative: 20-24 2019 13,337
PMTCT_STAT By Number of new negative: 50+ 2019 36
PMTCT_STAT By Number of new positives: 15-19 2019 40
PMTCT_STAT By Number of new positives: 20-24 2019 198
PMTCT_STAT Number of new ANC and L&D clients 2019 41,490
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 40,776
PMTCT_STAT_den 25-29, Female 2019 6,018
PMTCT_STAT_den 30-34, Female 2019 6,018
PMTCT_STAT_den 35-39, Female 2019 6,018
PMTCT_STAT_den 40-49, Female 2019 6,018
PMTCT_STAT_den By Age (Denominator): <15-19 2019 3,288
PMTCT_STAT_den By Age (Denominator): 10-14 2019 12
PMTCT_STAT_den By Age (Denominator): 20-24 2019 13,791
PMTCT_STAT_den By Age (Denominator): 50+ 2019 327
PrEP_NEW 25-29, Female 2019 83
PrEP_NEW 25-29, Male 2019 36
PrEP_NEW 30-34, Female 2019 60
PrEP_NEW 30-34, Male 2019 47
PrEP_NEW 35-39, Female 2019 60
PrEP_NEW 35-39, Male 2019 47
PrEP_NEW 40-49, Female 2019 60
PrEP_NEW 40-49, Male 2019 36
PrEP_NEW Female 15-19 2019 141
PrEP_NEW Female 20-24 2019 493
PrEP_NEW Female 50+ 2019 23
PrEP_NEW FSW 2019 167
PrEP_NEW Male 15-19 2019 12
PrEP_NEW Male 20-24 2019 70
PrEP_NEW Male 50+ 2019 23
PrEP_NEW MSM 2019 84
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 1,191
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 257
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 342
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 599
TB_PREV Alternative TPT Regimen, Life-long ART, Already, Positive 2019 2,927
TB_PREV Alternative TPT Regimen, Life-long ART, New, Positive 2019 1,959
TB_PREV By Age/Sex (Numerator): <15, Female 2019 900
TB_PREV By Age/Sex (Numerator): <15, Male 2019 900
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 3,601
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 2,779
TB_PREV IPT, Life-long ART, Already, Positive 2019 2,042
TB_PREV IPT, Life-long ART, New, Positive 2019 1,959
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 8,178
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 9,453
TB_PREV_den Alternative TPT Regimen, Life-long ART, Already, Positive 2019 3,116
TB_PREV_den Alternative TPT Regimen, Life-long ART, New, Positive 2019 2,081
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 1,034
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 1,034
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 4,156
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 3,208
TB_PREV_den IPT, Life-long ART, Already, Positive 2019 2,169
TB_PREV_den IPT, Life-long ART, New, Positive 2019 2,081
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 130
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 757
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 136
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1,533
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 2,559
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 2,598
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 115
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 778
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 131
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1,575
TX_CURR 25-29, Female, Positive 2019 6,453
TX_CURR 25-29, Male, Positive 2019 1,034
TX_CURR 30-34, Female, Positive 2019 5,702
TX_CURR 30-34, Male, Positive 2019 1,633
TX_CURR 35-39, Female, Positive 2019 4,888
TX_CURR 35-39, Male, Positive 2019 1,634
TX_CURR 40-49, Female, Positive 2019 3,366
TX_CURR 40-49, Male, Positive 2019 1,634
TX_CURR Age/Sex: <1 2019 25
TX_CURR Age/Sex: <1-9 2019 797
TX_CURR Age/Sex: 10-14 Female 2019 430
TX_CURR Age/Sex: 10-14 Male 2019 465
TX_CURR Age/Sex: 15-19 Female 2019 567
TX_CURR Age/Sex: 15-19 Male 2019 294
TX_CURR Age/Sex: 20-24 Female 2019 1,530
TX_CURR Age/Sex: 20-24 Male 2019 400
TX_CURR Age/Sex: 50+ Female 2019 2,666
TX_CURR Age/Sex: 50+ Male 2019 567
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 34,085
TX_CURR Sum of age/sex disaggregates 2019 861
TX_NEW 25-29, Female, Positive 2019 1,853
TX_NEW 25-29, Male, Positive 2019 298
TX_NEW 30-34, Female, Positive 2019 1,443
TX_NEW 30-34, Male, Positive 2019 462
TX_NEW 35-39, Female, Positive 2019 1,401
TX_NEW 35-39, Male, Positive 2019 462
TX_NEW 40-49, Female, Positive 2019 963
TX_NEW 40-49, Male, Positive 2019 462
TX_NEW Breastfeeding status 2019 107
TX_NEW By Age/Sex: <1 2019 4
TX_NEW By Age/Sex: 1-9 2019 229
TX_NEW By Age/Sex: 10-14 Female 2019 123
TX_NEW By Age/Sex: 10-14 Male 2019 128
TX_NEW By Age/Sex: 15-19 Female 2019 163
TX_NEW By Age/Sex: 15-19 Male 2019 84
TX_NEW By Age/Sex: 20-24 Female 2019 439
TX_NEW By Age/Sex: 20-24 Male 2019 114
TX_NEW By Age/Sex: 50+ Female 2019 764
TX_NEW By Age/Sex: 50+ Male 2019 163
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 9,555
TX_NEW Pregnancy status 2019 770
TX_NEW Sum of Age/Sex disaggregates 2019 1,978
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 33,279
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 3,993
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 328
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 3,993
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 328
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 13,646
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 1,667
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 7,657
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 1,667
TX_PVLS_den Denominator: Indication: Routine 2019 29,286
TX_PVLS_den Denominator: Indication: Targeted 2019 3,993
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 106
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 113
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 1,970
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 2,290
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 4,479
TX_RET Numerator by Status: Breastfeeding 2019 63
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 5,050
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 121
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 131
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 2,899
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 1,904
TX_RET_den Denominator by Status: Breastfeeding 2019 66
TX_RET_den Denominator by Status: Pregnant 2019 304
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 34,079
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 991
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 1,399
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 21,810
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 9,877
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 558
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 97
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 679
Cross Cutting Budget Categories and Known Amounts Total: $1,864,164
Key Populations: MSM and TG $87,000
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Key Populations: Sex Workers $130,500
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Gender: Gender Based Violence (GBV) $150,000
GBV Prevention
Implementation
Capacity building
Post GBV Care
Implementation
Capacity building
Gender: Gender Equality $150,000
Equity in HIV prevention, care, treatment and support
Implementation
Capacity building
Renovation $174,000
Human Resources for Health $1,172,664